LC
LAB icon

Lindbrook Capital’s Standard BioTools LAB Stock Holding History

Lindbrook Capital’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$976 Buy
+904
New +$1.27K ﹤0.01% 2463

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lindbrook Capital's LAB Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Standard BioTools (LAB) in Q1 2025: 904 shares worth $976. The stake represents ﹤0.01% of the portfolio and ranks #2463 among its holdings.

145 funds tracked by Wall St. Rank hold LAB as of Q1 2025.

  • Lindbrook Capital held 904 shares of Standard BioTools worth $976 as of Q1 2025.
  • Standard BioTools was a new Lindbrook Capital position in Q1 2025.
  • Standard BioTools made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2463 holding.
  • 145 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.